Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Ni
Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C
Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C Orphazyme continues to have hope for efficacy of arimoclomol in Amyotrophic Lateral Sclerosis . . . : |
All times are GMT -5. The time now is 04:07 AM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.